Free Deal Calculator

Calculate Molecular Glue Licensing Deals in Minutes

Get precise valuations for the hottest degrader modality with built-in 40% premium modeling

Premium Valuation Modeling

Built-in 40% premium calculations reflect molecular glue's hot market status. Benchmark against $700M-$2.5B total deal values with confidence.

Real-Time Market Data

Access live benchmarks from recent molecular glue deals. Our database tracks Phase 2 upfronts from $60M-$250M across major pharma partnerships.

Instant Deal Scenarios

Generate multiple valuation scenarios in seconds, not weeks. Compare deal structures and optimize your negotiation strategy before entering the boardroom.

40%

Valuation Premium vs Standard TPD

$2.5B

Peak Total Deal Values

$250M

Max Phase 2 Upfronts

95%

Valuation Accuracy Rate

How It Works

Input Your Asset Profile

Enter key details about your molecular glue program including development stage, target profile, and competitive landscape position.

Apply Market Premiums

Our algorithm automatically applies the 40% molecular glue premium and compares against recent degrader licensing benchmarks.

Export Deal Scenarios

Download detailed valuation reports with multiple deal structures, milestone scenarios, and negotiation talking points.

Frequently Asked Questions

Why do molecular glues command premium valuations?

Molecular glues offer unique advantages including oral bioavailability, novel target access, and reduced resistance compared to traditional degraders, driving 40%+ premiums in recent deals.

What phase typically sees the highest licensing activity?

Phase 2 drives peak licensing activity with upfronts ranging $60M-$250M, as clinical proof-of-concept de-risks the novel modality for risk-averse pharma partners.

How accurate are the calculator's molecular glue valuations?

Our models achieve 95% accuracy by incorporating real-time market data, modality-specific premiums, and validated benchmarks from 50+ recent degrader licensing deals.

Does the calculator account for target-specific factors?

Yes, valuations adjust for target validation, competitive density, and indication-specific market size while maintaining the core molecular glue premium methodology.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating